$10.02
7.63% yesterday
Nasdaq, May 20, 06:03 pm CET
ISIN
US71716E1055
Symbol
PHAR

Pharming Group N.V. - ADR Stock price

$10.02
+1.87 22.94% 1M
+2.34 30.47% 6M
-0.05 0.45% YTD
+1.02 11.33% 1Y
+1.84 22.49% 3Y
-6.68 40.00% 5Y
-6.68 40.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.71 7.63%
ISIN
US71716E1055
Symbol
PHAR
Sector
Industry

Key metrics

Market capitalization $681.67m
Enterprise Value $694.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 254.52
EV/Sales (TTM) EV/Sales 2.17
P/S ratio (TTM) P/S ratio 2.13
P/B ratio (TTM) P/B ratio 3.19
Revenue growth (TTM) Revenue growth 23.92%
Revenue (TTM) Revenue $320.29m
EBIT (operating result TTM) EBIT $6.27m
Free Cash Flow (TTM) Free Cash Flow $2.73m
Cash position $107.27m
EPS (TTM) EPS $-0.20
P/S forward 2.13
EV/Sales forward 2.17
Show more

Is Pharming Group N.V. - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Pharming Group N.V. - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pharming Group N.V. - ADR forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Pharming Group N.V. - ADR forecast:

Buy
100%

Financial data from Pharming Group N.V. - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
320 320
24% 24%
100%
- Direct Costs 38 38
2% 2%
12%
290 290
31% 31%
91%
- Selling and Administrative Expenses 193 193
20% 20%
60%
- Research and Development Expense 84 84
17% 17%
26%
19 19
266% 266%
6%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6.27 6.27
120% 120%
2%
Net Profit -13 -13
28% 28%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Pharming Group N.V. - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharming Group N.V. - ADR Stock News

Neutral
Seeking Alpha
12 days ago
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C.
Neutral
Seeking Alpha
2 months ago
Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Ben Jackson – Jefferies Alistair Campbell - RBC Capital Markets Joe Pantginis - H.C.
Neutral
GlobeNewsWire
3 months ago
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
More Pharming Group N.V. - ADR News

Company Profile

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.

Head office Netherlands
CEO Fabrice Chouraqui
Founded 1988
Website www.pharming.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today